Targeting the interleukin pathway in the treatment of asthma

The Lancet

Volumn 386, Issue 9998, 2015, Pages 1086-1096

  Chung, Kian Fan ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 157; BENRALIZUMAB; BIOLOGICAL MARKER; BRODALUMAB; CORTICOSTEROID; CYTOKINE; DUPILUMAB; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; LEBRIKIZUMAB; LIGELIZUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; PROSTAGLANDIN D2; QUILIZUMAB; RESLIZUMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRALOKINUMAB; TRANSCRIPTION FACTOR GATA 3; UNINDEXED DRUG; VIDUPIPRANT; ANTIASTHMATIC AGENT; INTERLEUKIN DERIVATIVE;

ALLERGIC ASTHMA; ARTICLE; ASTHMA; CELL INTERACTION; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HUMAN; LYMPHOID CELL; MODERATE PERSISTENT ASTHMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION; TH2 CELL; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; INTERLEUKINS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 84941584712     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00157-9     Document Type: Review

References (87)

1. Global Asthma Network Global asthma report 2014. Global burden of disease due to asthma http://www.globalasthmareport.org/burden/burden.php (accessed July 29, 2015).
2. S Accordini, AG Corsico, M Braggion et al. The cost of persistent asthma in Europe: an international population-based study in adults Int Arch Allergy Immunol 160 2013 93 101
3. Global Initiative for Asthma Global strategy for asthma management and prevention http://www.ginasthma.org/documents/4 2015 (accessed July 29, 2015).
4. KF Chung, SE Wenzel, JL Brozek et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Eur Respir J 43 2014 343 373
5. WC Moore, ER Bleecker, D Curran-Everett the National Heart Lung Blood Institute's Severe Asthma Research Program Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program J Allergy Clin Immunol 119 2007 405 413
6. European Network for Understanding Mechanisms of Severe Asthma The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur Respir J 22 2003 470 477
7. IM Adcock, G Caramori, KF Chung New targets for drug development in asthma Lancet 372 2008 1073 1087
8. BN Lambrecht, H Hammad Allergens and the airway epithelium response: gateway to allergic sensitization J Allergy Clin Immunol 134 2014 499 507
9. ST Holgate Innate and adaptive immune responses in asthma Nat Med 18 2012 673 683
10. DJ Erle, D Sheppard The cell biology of asthma J Cell Biol 205 2014 621 631
11. KF Chung, PJ Barnes Cytokines in asthma Thorax 54 1999 825 857
12. MJ Schuijs, MA Willart, H Hammad et al. Cytokine targets in airway inflammation Curr Opin Pharmacol 13 2013 351 361
13. WC Moore, DA Meyers, SE Wenzel the National Heart Lung Blood Institute's Severe Asthma Research Program Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program Am J Respir Crit Care Med 181 2010 315 323
14. P Haldar, ID Pavord, DE Shaw et al. Cluster analysis and clinical asthma phenotypes Am J Respir Crit Care Med 178 2008 218 224
15. KF Chung, IM Adcock How variability in clinical phenotypes should guide research into disease mechanisms in asthma Ann Am Thorac Soc 10 suppl 2013 S109 S117
16. PG Woodruff, HA Boushey, GM Dolganov et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids Proc Natl Acad Sci USA 104 2007 15858 15863
17. PG Woodruff, B Modrek, DF Choy et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
18. SE Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches Nat Med 18 2012 716 725
19. KF Chung Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies J Intern Med 2015 10.1111/joim.12382 published online June 15.
20. P Flood-Page, C Swenson, I Faiferman the International Mepolizumab Study Group A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
21. ID Pavord, S Korn, P Howarth et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
22. F Schleich, G Brusselle, R Louis et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR) Respir Med 108 2014 1723 1732
23. AH Wagener, SB de Nijs, R Lutter et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma Thorax 70 2015 115 120
24. MC Peters, ZK Mekonnen, S Yuan et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma J Allergy Clin Immunol 133 2014 388 394 e5.
25. LE Katz, GJ Gleich, BF Hartley et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma Ann Am Thorac Soc 11 2014 531 536
26. G Jia, RW Erickson, DF Choy et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 130 2012 647 654 e10.
27. J Corren, RF Lemanske, NA Hanania et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
28. CM Lloyd, S Saglani Epithelial cytokines and pulmonary allergic inflammation Curr Opin Immunol 34 2015 52 58
29. P Licona-Limón, LK Kim, NW Palm et al. TH2, allergy and group 2 innate lymphoid cells Nat Immunol 14 2013 536 542
30. R Djukanović, SJ Wilson, M Kraft et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
31. JV Fahy, HE Fleming, HH Wong et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
32. EL van Rensen, CE Evertse, WA van Schadewijk et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment Allergy 64 2009 72 80
33. Djukanovic R, Wilson SJ, Kraft M, et al. Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. American Thoracic Society 99th international conference; Seattle, WA, USA; May 16-21, 2003. Abstract 703.
34. R Normansell, S Walker, SJ Milan et al. Omalizumab for asthma in adults and children Cochrane Database Syst Rev 1 2014 CD003559
35. M Humbert, R Beasley, J Ayres et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
36. NA Hanania, S Wenzel, K Rosén et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
37. JP Arm, I Bottoli, A Skerjanec et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects Clin Exp Allergy 44 2014 1371 1385
38. GM Gauvreau, JM Harris, LP Boulet et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production Sci Transl Med 6 2014 243ra85
39. T Maes, GF Joos, GG Brusselle Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol 47 2012 261 270
40. M Wills-Karp, J Luyimbazi, X Xu et al. Interleukin-13: central mediator of allergic asthma Science 282 1998 2258 2261
41. S Wenzel, D Wilbraham, R Fuller et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431
42. RE Slager, BA Otulana, GA Hawkins et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist J Allergy Clin Immunol 130 2012 516 522 e4.
43. Wenzel SEIP, Otulana BA, Bleecker ER, et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist reduced exacerbations in patients with eosinophilic asthma. ERS annual congress 2010; Barcelona; Sept 18-22, 2010. Abstract 3980.
44. J Corren, W Busse, EO Meltzer et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma Am J Respir Crit Care Med 181 2010 788 796
45. S Wenzel, L Ford, D Pearlman et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466
46. Wenzel SE, Wang L, Pirozzi G, et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. 2015 Meeting of the American Thoracic Society; Denver, CO, USA; May 15-20, 2015. Abstract A6362.
47. H Scheerens, JR Arron, Y Zheng et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge Clin Exp Allergy 44 2014 38 46
48. NA Hanania, M Noonan, J Corren et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies Thorax 70 2015 748 756
49. E Piper, C Brightling, R Niven et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Eur Respir J 41 2013 330 338
50. CE Brightling, P Chanez, R Leigh et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial Lancet Respir Med 2015 published online July 28. http://dx.doi.org/10.1016/S2213-2600(15)00197-6
51. EH De Boever, C Ashman, AP Cahn et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial J Allergy Clin Immunol 133 2014 989 996
52. MJ Leckie, A ten Brinke, J Khan et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
53. P Haldar, CE Brightling, B Hargadon et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
54. P Nair, MM Pizzichini, M Kjarsgaard et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
55. HG Ortega, MC Liu, ID Pavord the MENSA Investigators Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
56. EH Bel, SE Wenzel, PJ Thompson the SIRIUS Investigators Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
57. M Castro, S Mathur, F Hargreave the Res-5-0010 Study Group Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
58. M Castro, J Zangrilli, ME Wechsler et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Lancet Respir Med 3 2015 355 366
59. M Castro, SE Wenzel, ER Bleecker et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study Lancet Respir Med 2 2014 879 890
60. RM Nowak, JM Parker, RA Silverman et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma Am J Emerg Med 33 2015 14 20
61. LC Borish, HS Nelson, MJ Lanz et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial Am J Respir Crit Care Med 160 1999 1816 1823
62. LC Borish, HS Nelson, J Corren the IL-4R Asthma Study Group Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J Allergy Clin Immunol 107 2001 963 970
63. M Noonan, P Korenblat, S Mosesova et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids J Allergy Clin Immunol 132 2013 567 574 e12.
64. P Nair Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma N Engl J Med 371 2014 1249 1251
65. R Kolbeck, A Kozhich, M Koike et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function J Allergy Clin Immunol 125 2010 1344 1353 e2.
66. H Kouzaki, SM O'Grady, CB Lawrence et al. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2 J Immunol 183 2009 1427 1434
67. B Bleck, G Grunig, A Chiu et al. MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells J Immunol 190 2013 3757 3763
68. YJ Liu, V Soumelis, N Watanabe et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation Annu Rev Immunol 25 2007 193 219
69. D Préfontaine, J Nadigel, F Chouiali et al. Increased IL-33 expression by epithelial cells in bronchial asthma J Allergy Clin Immunol 125 2010 752 754
70. S Ying, B O'Connor, J Ratoff et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease J Immunol 181 2008 2790 2798
71. J Wu, F Liu, J Zhao et al. Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway Cell Biochem Funct 31 2013 496 503
72. GM Gauvreau, PM O'Byrne, LP Boulet et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses N Engl J Med 370 2014 2102 2110
73. R Pettipher, TT Hansel, R Armer Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases Nat Rev Drug Discov 6 2007 313 325
74. N Barnes, I Pavord, A Chuchalin et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin Exp Allergy 42 2012 38 48
75. WW Busse, SE Wenzel, EO Meltzer et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients J Allergy Clin Immunol 131 2013 339 345
76. IP Hall, AV Fowler, A Gupta et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment Pulm Pharmacol Ther 32 2015 37 44
77. Berair RGS, Singapuri A, Hartley R, et al. Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CrTh2) antagonist upon sputum and bronchial eosinophilic inflammation and clinical outcomes in treatment-resistant asthma: a phase 2a randomised placebo-controlled trial. 2015 Meeting of the American Thoracic Society; Denver, CO, USA; May 15-20, 2015. Abstract A6361.
78. L Roussel, F Houle, C Chan et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation J Immunol 184 2010 4531 4537
79. R Halwani, S Al-Muhsen, Q Hamid T helper 17 cells in airway diseases: from laboratory bench to bedside Chest 143 2013 494 501
80. H Vroman, B van den Blink, M Kool Mode of dendritic cell activation: the decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity? Immunobiology 220 2015 254 261
81. W Al-Ramli, D Préfontaine, F Chouiali et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma J Allergy Clin Immunol 123 2009 1185 1187
82. WW Busse, S Holgate, E Kerwin et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma Am J Respir Crit Care Med 188 2013 1294 1302
83. O Holz, S Khalilieh, A Ludwig-Sengpiel et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects Eur Respir J 35 2010 564 570
84. P Nair, M Gaga, E Zervas the Study Investigators Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial Clin Exp Allergy 42 2012 1097 1103
85. MA Berry, B Hargadon, M Shelley et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma N Engl J Med 354 2006 697 708
86. JB Morjaria, AJ Chauhan, KS Babu et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial Thorax 63 2008 584 591
87. SE Wenzel, PJ Barnes, ER Bleecker the T03 Asthma Investigators A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma Am J Respir Crit Care Med 179 2009 549 558